Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress, 21435 [05-8299]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 79 / Tuesday, April 26, 2005 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Nitroxides as Protectors
Against Oxidative Stress
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
license worldwide to practice the
invention embodied in U.S. Patent
5,792,775, issued on August 11, 1998,
entitled ‘‘Nitroxides as Protectors
Against Oxidative Stress,’’ to Mitos, Inc.
having a place of business in the State
of California. The field of use may be
limited to therapeutics for the treatment
and/or protection of tissue damage
caused by ionization radiation. The
United States of America is the assignee
of the patent rights in this invention.
This announcement is the first notice to
grant an exclusive license to this
technology.
DATES: Only written comments and/or
application for a license which are
received by the NIH Office of
Technology Transfer on or before June
27, 2005 will be considered.
ADDRESSES: Requests for a copy of the
patent, inquiries, comments and other
materials relating to the contemplated
license should be directed to: Pradeep
Ghosh, J.D., Ph.D., M.B.A., Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
telephone: (301) 435–5282; Facsimile:
(301) 402–0220; e-mail:
ghoshpr@mail.nih.gov.]
This
technology relates to to the use of a
biologically compatible composition
containing an effective amount of a
metal independent nitroxide compound
as an antioxidant capable of protecting
cells, tissues, organs, and whole
organisms against deleterious effects of
harmful oxygen-derived species
generated during oxidative stress
SUPPLEMENTARY INFORMATION:
VerDate jul<14>2003
11:52 Apr 25, 2005
Jkt 205001
induced by ionizing radiations.
Nitroxides are low molecular weight
molecules and easily soluble in aqueous
solutions. They are active within the
biological pH range of 5–8, non-toxic at
effective concentrations and can be
easily attached to several organic
molecules that may facilitate targeting of
the molecules to specific organs or
organelles. These properties of
nitroxides make them ideal for
treatment and protection of radiation
induced cellular and tissue damages.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within 60 days from the date of this
published Notice, NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: April 18, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–8299 Filed 4–25–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration will publish
periodic summaries of proposed
projects. To request more information
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
21435
on the proposed projects or to obtain a
copy of the information collection
plans, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: 2005 Client/Patient
Sample Survey—New
The Substance Abuse and Mental
Health Services Administration
(SAMHSA), Center for Mental Health
Services (CMHS) will conduct a sample
survey of mental health programs (i.e.,
inpatient, residential, and less than 24hour care) within specialty mental
health organizations. These
organizations include psychiatric
hospitals, general hospitals with
separate psychiatric services,
multiservice mental health
organizations, residential treatment
centers, and freestanding outpatient
clinics and partial care organizations.
A sample of approximately 2,500
mental health organizations/programs
will provide information on an average
sample of 8 admissions and 8 persons
under care in the programs. National
estimates will be generated on the
number of persons admitted to and
under care in these organizations, and
on the sociodemographic, clinical, and
service use characteristics of these
persons. This survey will update a
previous sample survey conducted in
1997 (OMB No. 0930–0114).
In addition, the 2005 survey will
include a consumer survey for the
sampled adults under care in the less
than 24-hour programs to obtain
consumers’ perceptions of care received.
Respondents will have the option of
responding electronically.
The annual burden estimate is shown
below:
E:\FR\FM\26APN1.SGM
26APN1
]]>Agencies
[Federal Register Volume 70, Number 79 (Tuesday, April 26, 2005)]
[Notices]
[Page 21435]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-8299]
[[Page 21435]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Nitroxides as Protectors
Against Oxidative Stress
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in
U.S. Patent 5,792,775, issued on August 11, 1998, entitled ``Nitroxides
as Protectors Against Oxidative Stress,'' to Mitos, Inc. having a place
of business in the State of California. The field of use may be limited
to therapeutics for the treatment and/or protection of tissue damage
caused by ionization radiation. The United States of America is the
assignee of the patent rights in this invention. This announcement is
the first notice to grant an exclusive license to this technology.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before June 27,
2005 will be considered.
ADDRESSES: Requests for a copy of the patent, inquiries, comments and
other materials relating to the contemplated license should be directed
to: Pradeep Ghosh, J.D., Ph.D., M.B.A., Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
telephone: (301) 435-5282; Facsimile: (301) 402-0220; e-mail:
ghoshpr@mail.nih.gov.]
SUPPLEMENTARY INFORMATION: This technology relates to to the use of a
biologically compatible composition containing an effective amount of a
metal independent nitroxide compound as an antioxidant capable of
protecting cells, tissues, organs, and whole organisms against
deleterious effects of harmful oxygen-derived species generated during
oxidative stress induced by ionizing radiations. Nitroxides are low
molecular weight molecules and easily soluble in aqueous solutions.
They are active within the biological pH range of 5-8, non-toxic at
effective concentrations and can be easily attached to several organic
molecules that may facilitate targeting of the molecules to specific
organs or organelles. These properties of nitroxides make them ideal
for treatment and protection of radiation induced cellular and tissue
damages.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: April 18, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-8299 Filed 4-25-05; 8:45 am]
BILLING CODE 4140-01-P
